Online inquiry

IVTScrip™ mRNA-Anti-TNFSF13&TNFSF13B, TACI-Fc(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ15216MR)

This product GTTS-WQ15216MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & 5-Methoxy-UTP. It ecodes the monoclonal antibody that targets TNFSF13&TNFSF13B gene. The antibody can be applied in Non-Hodgkin's lymphoma (NHL), Rheumatoid arthritis (RA) research.
Specifications
Product type mRNA
Modified bases 5-Methoxy-UTP
5' Cap Cap 1
Species Homo sapiens
RefSeq NM_001198622.2; NM_001145645.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 8741; 10673
UniProt ID Q2QBA2; Q9Y275
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-TNFSF13&TNFSF13B, TACI-Fc(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) (GTTS-WQ15216MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ7722MR IVTScrip™ mRNA-Anti-GLP1R, GLP-1Fc(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA GLP-1Fc
GTTS-WQ5604MR IVTScrip™ mRNA-Anti-KDR, CDP791(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA CDP791
GTTS-WQ4451MR IVTScrip™ mRNA-Anti-SLAMF7, BMS-901608(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA BMS-901608
GTTS-WQ13842MR IVTScrip™ mRNA-Anti-GCGR, REGN-1193(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA REGN-1193
GTTS-WQ12197MR IVTScrip™ mRNA-Anti-CSF2, MORAb-022(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA MORAb-022
GTTS-WQ13098MR IVTScrip™ mRNA-Anti-ACVRL1, PF-03446962(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA PF-03446962
GTTS-WQ924MR IVTScrip™ mRNA-Anti-EGFR, ABBV-321(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA ABBV-321
GTTS-WQ7771MR IVTScrip™ mRNA-Anti-MMP9, GS-5745(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA GS-5745
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW